Adar1 Capital Management portfolio · Q2 2026
ADAR1 Capital Management, LLC · CIK 0001940272 ·13F filings on SEC EDGAR
In Q2 2026, ADAR1 Capital Management, LLC reported 277 positions worth $2.2B. Its largest holding was ABVX at 11.0% of the portfolio, and the top 10 made up 41%. Its largest new position was EDIT ($28.8M), and it sold out of TERN.
- NEW 46
- ADD 100
- REDUCE 64
- EXIT 79
Portfolio map
Each box is a position sized by its value. Color shows the change in shares from the previous quarter. The smallest 237 positions are grouped as one box.
Portfolio history
Q4 2025 to Q2 2026, 3 quarters
Weight of the largest holdings
The 7 holdings with the highest weight in any quarter shown, stacked with all others to 100%.
Holding timeline
Shade shows the weight in each quarter. A blank cell means the holding was not reported that quarter.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
ABVX ABIVAX SA-ADR | 11.01% | $40.83 | $99.02 | +142.5% | $178.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PTGX PROTAGONIST THERAPEUTICS INC | 5.39% | $36.15* | $140.89 | +289.8% | $135.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ROIV ROIVANT SCIENCES LTD | 5.11% | $12.90* | $36.57 | +183.6% | $115.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPY SS SPDR S&P 500 ETF TRUST-US | 4.41% | $688.26 | $762.63 | +10.8% | $98.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMVT IMMUNOVANT INC | 4.11% | $19.64* | $33.78 | +72.0% | $78.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZLAB ZAI LAB LTD-ADR | 2.93% | $20.48* | $26.34 | +28.6% | $88.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AGIO AGIOS PHARMACEUTICALS INC | 2.19% | $36.10 | $33.25 | -7.9% | $42.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRNX CRINETICS PHARMACEUTICALS IN | 2.09% | $38.17 | $37.42 | -2.0% | $45.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BOXX ALPHA ARCHITECT 1-3 MNTH BOX | 1.81% | $106.78 | $118.39 | +10.9% | $39.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CYTK CYTOKINETICS INC | 1.79% | $54.28* | $65.91 | +21.4% | $30.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SEPN SEPTERNA INC | 1.44% | $9.95 | $39.13 | +293.4% | $36.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVR ANTERIS TECHNOLOGIES GLOBAL | 1.42% | $5.36 | $7.77 | +45.0% | $24.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EDIT EDITAS MEDICINE INC | 1.32% | $3.24 | $2.57 | -20.7% | $22.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DNLI DENALI THERAPEUTICS INC | 1.21% | $19.16 | $20.67 | +7.9% | $21.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SYRE SPYRE THERAPEUTICS INC | 1.15% | $46.92 | $89.03 | +89.7% | $25.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VIR VIR BIOTECHNOLOGY INC | 1.15% | $8.96 | $11.18 | +24.8% | $27.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRAX PRAXIS PRECISION MEDICINES I | 1.14% | $333.98 | $291.23 | -12.8% | $21.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INSM INSMED INC | 1.12% | $115.43 | $114.14 | -1.1% | $26.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLDX CELLDEX THERAPEUTICS INC | 1.05% | $29.75 | $32.41 | +9.0% | $20.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VKTX VIKING THERAPEUTICS INC | 1.02% | $36.17* | $32.60 | -9.9% | $18.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TSHA TAYSHA GENE THERAPIES INC | 0.95% | $2.51* | $4.87 | +93.7% | $14.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MNPR MONOPAR THERAPEUTICS INC | 0.92% | $49.36 | $79.67 | +61.4% | $17.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OVID OVID THERAPEUTICS INC | 0.91% | $2.06* | $2.49 | +20.8% | $18.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELVN ENLIVEN THERAPEUTICS INC | 0.90% | $39.09 | $45.84 | +17.3% | $17.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENTA ENANTA PHARMACEUTICALS INC | 0.90% | $14.60 | $13.18 | -9.7% | $17.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.86% | — | — | — | $18.8M | |
| 0.85% | — | — | — | $18.7M | |
NKTR NEKTAR THERAPEUTICS | 0.78% | $64.77 | $60.54 | -6.5% | $14.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INSP INSPIRE MEDICAL SYSTEMS INC | 0.76% | $50.91 | $69.36 | +36.2% | $26M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMD REVOLUTION MEDICINES INC | 0.75% | $45.37 | $205.26 | +352.4% | $18M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ESTA ESTABLISHMENT LABS HOLDINGS | 0.73% | $56.29 | $64.17 | +14.0% | $11.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRTA PROTHENA CORP PLC | 0.70% | $6.36 | $8.38 | +31.9% | $13M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 0.69% | $80.97 | $95.22 | +17.6% | $13M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IKT INHIBIKASE THERAPEUTICS INC | 0.69% | $2.72 | $2.06 | -24.5% | $15.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QURE UNIQURE NV | 0.68% | $45.45 | $24.16 | -46.8% | $7.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLYB RALLYBIO CORP | 0.68% | $15.84 | $17.20 | +8.6% | $15.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
REGN REGENERON PHARMACEUTICALS | 0.63% | $605.67 | $758.27 | +25.2% | $16.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IVA INVENTIVA SA - ADR | 0.62% | $4.30 | $3.69 | -14.3% | $13.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STRO SUTRO BIOPHARMA INC | 0.61% | $23.20 | $16.11 | -30.6% | $6.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IONS IONIS PHARMACEUTICALS INC | 0.60% | $46.93 | $44.65 | -4.9% | $7.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BBIO BRIDGEBIO PHARMA INC | 0.60% | $50.66* | $65.80 | +29.9% | $11.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRPT SAREPTA THERAPEUTICS INC | 0.60% | $20.09* | $18.22 | -9.3% | $13.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTMX CYTOMX THERAPEUTICS INC | 0.58% | $2.54 | $2.72 | +7.2% | $9.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VOR VOR BIOPHARMA INC | 0.57% | $18.41 | $19.08 | +3.6% | $13M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIL SS SPDR BB 1-3M T-BILL ETF | 0.57% | $91.43* | $91.64 | +0.2% | $12.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EQ EQUILLIUM INC | 0.55% | $1.45 | $1.62 | +12.4% | $6.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANL ADLAI NORTYE GROUP LTD | 0.54% | $10.97 | $16.00 | +45.9% | $16.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLYM CLIMB BIO INC | 0.49% | $7.36 | $11.47 | +55.8% | $9.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XBIPut SS SPDR S&P BIOTECH ETF | 0.49% | — | — | — | $10.7M |
HLXC HELIX ACQUISITION CORP-CL A | 0.49% | $10.23 | $10.57 | +3.3% | $10.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZURA ZURA BIO LTD | 0.48% | $5.09 | $4.16 | -18.2% | $7.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OKUR ONKURE THERAPEUTICS INC-A | 0.47% | $3.62 | $2.72 | -24.8% | $6.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MAZE MAZE THERAPEUTICS INC | 0.46% | $31.22 | $27.18 | -12.9% | $9.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XENE XENON PHARMACEUTICALS INC | 0.46% | $36.93 | $37.19 | +0.7% | $6.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
881624209 TEVA PHARMACEUTICAL INDS LTD | 0.43% | $17.35* | $33.88 | +95.3% | $9.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
URGN UROGEN PHARMA LTD | 0.43% | $19.24 | $40.63 | +111.2% | $10.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FTH FAETH THERAPEUTICS INC | 0.41% | $25.00 | $29.74 | +19.0% | $10.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AMLX AMYLYX PHARMACEUTICALS INC | 0.41% | $4.89 | $29.10 | +495.4% | $14.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DBVT DBV TECHNOLOGIES SA-SPON ADR | 0.40% | $20.89 | $11.76 | -43.7% | $6.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SVRA SAVARA INC | 0.40% | $2.86 | $5.16 | +80.4% | $7.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PCVX VAXCYTE INC | 0.39% | $38.43 | $56.90 | +48.1% | $8.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CGON CG ONCOLOGY INC | 0.39% | $29.67 | $70.89 | +138.9% | $8.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MLYS MINERALYS THERAPEUTICS INC | 0.37% | $24.96 | $25.13 | +0.7% | $7.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASND ASCENDIS PHARMA A/S | 0.35% | $266.72 | $227.83 | -14.6% | $6.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AMAN AMANAT ACQUISITION CORP CL A | 0.35% | $10.16 | $10.67 | +5.0% | $8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NRIX NURIX THERAPEUTICS INC | 0.35% | $22.94 | $23.71 | +3.3% | $7.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BHVN BIOHAVEN LTD | 0.34% | $14.97 | $13.35 | -10.8% | $6.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRME PRIME MEDICINE INC | 0.34% | $3.48 | $3.05 | -12.3% | $6.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FRNM FREENOME INC | 0.34% | $10.33 | $10.88 | +5.3% | $7.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRD OPUS GENETICS INC | 0.34% | $4.50 | $4.84 | +7.7% | $8.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LXEO LEXEO THERAPEUTICS INC | 0.33% | $6.54 | $3.38 | -48.3% | $5.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
36322Q206 DAMORA THERAPEUTICS INC | 0.33% | $25.90 | $26.01 | +0.4% | $7.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
REPL REPLIMUNE GROUP INC | 0.33% | $5.89 | $13.24 | +124.9% | $8.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LONA LEONABIO INC | 0.33% | $8.78 | $3.57 | -59.3% | $2.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KRRO KORRO BIO INC | 0.33% | $11.32 | $9.91 | -12.5% | $5.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RACC RESEARCH ALLIANCE CORP CL A | 0.32% | $10.70 | $10.83 | +1.2% | $7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IFRX INFLARX NV | 0.31% | $2.17 | $1.80 | -17.0% | $5.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLAY RELAY THERAPEUTICS INC | 0.31% | $18.71 | $18.05 | -3.5% | $6.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JANX JANUX THERAPEUTICS INC | 0.30% | $21.18 | $17.28 | -18.4% | $7.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PLRX PLIANT THERAPEUTICS INC | 0.29% | $1.20 | $1.08 | -9.7% | $6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
WHWK WHITEHAWK THERAPEUTICS INC | 0.28% | $4.41 | $3.76 | -14.8% | $5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KRYS KRYSTAL BIOTECH INC | 0.28% | $181.75 | $332.56 | +83.0% | $5.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABUS ARBUTUS BIOPHARMA CORP | 0.28% | $3.83* | $4.78 | +24.9% | $6.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PFE PFIZER INC | 0.28% | $24.82* | $28.52 | +14.9% | $7.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BHF BRIGHTHOUSE FINANCIAL INC | 0.28% | $63.56 | $49.90 | -21.5% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.27% | — | — | — | $5.9M | |
EWTX EDGEWISE THERAPEUTICS INC | 0.27% | $28.61 | $40.60 | +41.9% | $5.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALEC ALECTOR INC | 0.27% | $1.85 | $1.85 | +0.2% | $5.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FULC FULCRUM THERAPEUTICS INC | 0.26% | $4.23* | $3.70 | -12.6% | $5.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARWR ARROWHEAD PHARMACEUTICALS IN | 0.26% | $29.34* | $65.45 | +123.1% | $4.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABOS ACUMEN PHARMACEUTICALS INC | 0.26% | $1.89 | $2.22 | +17.7% | $4.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OACCU OAKTREE ACQUISITION III LIFE | 0.26% | $10.14 | $10.89 | +7.4% | $5.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GMED GLOBUS MEDICAL INC - A | 0.25% | $81.39 | $74.90 | -8.0% | $5.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GLUE MONTE ROSA THERAPEUTICS INC | 0.24% | $7.49 | $11.93 | +59.3% | $2.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DGAC.U DISCIPLINED GROWTH ACQUISITI | 0.23% | $10.04 | $10.04 | 0.0% | $5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BHAVU BHAV ACQUISITION CORP | 0.23% | $9.97 | $10.15 | +1.8% | $5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.23% | — | — | — | $5M | |
| 0.23% | — | — | — | $4.9M | |
DHR DANAHER CORP | 0.23% | $222.14 | $221.55 | -0.3% | $5.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BOLD BOUNDLESS BIO INC | 0.23% | $2.50 | $2.51 | +0.4% | $4.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVLN AVALYN PHARMA INC | 0.22% | $32.92 | $28.49 | -13.5% | $4.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPRY ARS PHARMACEUTICALS INC | 0.22% | $8.94 | $4.31 | -51.8% | $2.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ATAI ATAIBECKLEY INC | 0.22% | $3.54 | $5.27 | +48.9% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRLD PRELUDE THERAPEUTICS INC | 0.22% | $5.01 | $3.91 | -21.9% | $3.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JATT JATT II ACQUISITION CORP | 0.22% | $11.36 | $11.18 | -1.6% | $4.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RNTX REIN THERAPEUTICS INC | 0.21% | $1.04 | $0.80 | -22.7% | $3.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PEPG PEPGEN INC | 0.21% | $1.80 | $2.42 | +34.7% | $6.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTNM CONTINEUM THERAPEUTICS INC-A | 0.21% | $11.34 | $13.42 | +18.3% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CATX PERSPECTIVE THERAPEUTICS INC | 0.19% | $3.77 | $2.75 | -27.0% | $3.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
APGE APOGEE THERAPEUTICS INC | 0.19% | $132.73 | $132.73 | 0.0% | $4.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NAMS NEWAMSTERDAM PHARMA CO NV | 0.18% | $18.89 | $24.32 | +28.7% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRBP CORBUS PHARMACEUTICALS HOLDI | 0.18% | $8.65 | $6.82 | -21.1% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIIB BIOGEN INC | 0.18% | $178.89 | $225.88 | +26.3% | $4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XNCR XENCOR INC | 0.17% | $15.12 | $24.95 | +65.1% | $5.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SLN SILENCE THERAPEUTICS PLC-ADR | 0.17% | $8.95* | $10.93 | +22.1% | $3.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPRB SPRUCE BIOSCIENCES INC | 0.17% | $82.46 | $48.58 | -41.1% | $3.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PHVS PHARVARIS NV | 0.17% | $24.56 | $31.72 | +29.1% | $3.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENGN ENGENE THERAPEUTICS INC | 0.17% | $1.73 | $2.00 | +15.6% | $4.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PALI PALISADE BIO INC | 0.17% | $2.28 | $1.35 | -40.8% | $2.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TARA PROTARA THERAPEUTIC INC | 0.16% | $5.33 | $3.05 | -42.8% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.16% | — | — | — | $3.5M | |
SGMT SAGIMET BIOSCIENCES INC-A | 0.15% | $7.73 | $9.88 | +27.8% | $4.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ONC BEONE MEDICINES LTD-ADR | 0.15% | $296.97 | $365.94 | +23.2% | $4.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IVVD INVIVYD INC | 0.15% | $1.10 | $0.87 | -20.9% | $3.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TENX TENAX THERAPEUTICS INC | 0.15% | $13.21 | $56.70 | +329.3% | $12.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZNTL ZENTALIS PHARMACEUTICALS INC | 0.14% | $4.16 | $2.77 | -33.4% | $1.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLMD RELMADA THERAPEUTICS INC | 0.14% | $6.81 | $3.77 | -44.7% | $1.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DCTH DELCATH SYSTEMS INC | 0.13% | $6.94* | $15.97 | +130.1% | $3.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BMRN BIOMARIN PHARMACEUTICAL INC | 0.13% | $58.85 | $60.00 | +2.0% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SMMT SUMMIT THERAPEUTICS INC | 0.13% | $17.52 | $16.91 | -3.5% | $3.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KROS KEROS THERAPEUTICS INC | 0.12% | $10.96* | $11.40 | +4.0% | $2.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ELDN ELEDON PHARMACEUTICALS INC | 0.12% | $1.51 | $2.53 | +67.5% | $1.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SNY SANOFI-ADR | 0.11% | $48.01 | $41.23 | -14.1% | $2.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AEXA AMERICAN EXCEPTIONALISM-CL A | 0.11% | $11.33 | $11.14 | -1.6% | $2.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TNGX TANGO THERAPEUTICS INC | 0.11% | $16.67 | $24.95 | +49.7% | $1.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ISRG INTUITIVE SURGICAL INC | 0.11% | $434.72 | $406.63 | -6.5% | $2.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INO INOVIO PHARMACEUTICALS INC | 0.11% | $1.16 | $1.22 | +5.2% | $2.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OABI OMNIAB INC | 0.11% | $2.11* | $2.46 | +16.5% | $2.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CAPR CAPRICOR THERAPEUTICS INC | 0.10% | $30.40 | $37.88 | +24.6% | $3.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DRUG BRIGHT MINDS BIOSCIENCES INC | 0.10% | $73.49 | $49.82 | -32.2% | $1.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ORKA ORUKA THERAPEUTICS INC | 0.09% | $10.33 | $83.29 | +706.6% | $1.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
92941V308 VYNE THERAPEUTICS INC | 0.09% | $0.63 | $0.65 | +3.3% | $1.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MCK MCKESSON CORP | 0.09% | $786.65 | $853.81 | +8.5% | $2.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LXRX LEXICON PHARMACEUTICALS INC | 0.08% | $1.56 | $1.88 | +20.2% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRVS CORVUS PHARMACEUTICALS INC | 0.08% | $9.51 | $11.52 | +21.2% | $1.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CUE CUE BIOPHARMA INC | 0.08% | $31.56 | $25.87 | -18.0% | $1.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MSLE SATELLOS BIOSCIENCE INC | 0.08% | $5.63 | $8.50 | +51.0% | $1.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KNSA KINIKSA PHARMACEUTICALS INTE | 0.08% | $28.05 | $74.61 | +166.0% | $2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTB CONNECT BIOPHARMA HOLDINGS L | 0.08% | $2.62 | $1.10 | -58.0% | $770K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CCIIU COHEN CIRCLE ACQUISITION COR | 0.07% | $10.28 | $10.46 | +1.8% | $1.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RCKT ROCKET PHARMACEUTICALS INC | 0.07% | $6.83 | $2.63 | -61.5% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TRAX FIRST TRACKS BIOTHERAPEUTICS | 0.07% | $20.12 | $35.44 | +76.1% | $2.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EVMN EVOMMUNE INC | 0.06% | $17.12 | $8.26 | -51.8% | $859.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CCCC C4 THERAPEUTICS INC | 0.06% | $4.37 | $3.33 | -23.8% | $972.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCRX BIOCRYST PHARMACEUTICALS INC | 0.06% | $9.04 | $8.33 | -7.8% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
868459108 SUPERNUS PHARMACEUTICALS | 0.06% | $48.77 | $43.04 | -11.8% | $1.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NVO NOVO-NORDISK A/S-SPONS ADR | 0.06% | $36.75 | $37.91 | +3.2% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVTR AVANTOR INC | 0.06% | $10.85 | $15.05 | +38.7% | $2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
457637700 INMED PHARMACEUTICALS INC | 0.06% | $1.55 | $1.55 | 0.0% | $1.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PMN PROMIS NEUROSCIENCES INC | 0.06% | $12.70 | $10.52 | -17.2% | $976.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.05% | — | — | — | $1.2M | |
ARTV ARTIVA BIOTHERAPEUTICS INC | 0.05% | $9.70 | $7.12 | -26.6% | $844.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TNYA TENAYA THERAPEUTICS INC | 0.05% | $0.71 | $0.60 | -15.3% | $938.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALXO ALX ONCOLOGY HOLDINGS INC | 0.05% | $2.07 | $1.39 | -32.9% | $741.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARE ALEXANDRIA REAL ESTATE EQUIT | 0.05% | $48.53 | $47.46 | -2.2% | $925.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RNAC CARTESIAN THERAPEUTICS INC | 0.05% | $10.42 | $7.21 | -30.8% | $712.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
23255M204 CYCLERION THERAPEUTICS INC | 0.05% | $3.39 | $3.39 | 0.0% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EA ELECTRONIC ARTS INC | 0.05% | $201.70 | $205.04 | +1.7% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
89422GAB3 TRAVERE THERAPEUTICS INC PRN | 0.05% | — | — | — | $1M |
BNTX BIONTECH SE-ADR | 0.05% | $98.30 | $98.30 | 0.0% | $1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACAD ACADIA PHARMACEUTICALS INC | 0.05% | $25.30 | $20.15 | -20.4% | $784.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DYN DYNE THERAPEUTICS INC | 0.04% | $12.87 | $16.11 | +25.2% | $689.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MPLT MAPLIGHT THERAPEUTICS INC | 0.04% | $20.33 | $10.19 | -49.9% | $270K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GPCR STRUCTURE THERAPEUTICS INC | 0.04% | $53.67 | $31.27 | -41.7% | $547.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KVACFCall KEEN VISION ACQUISITION CORP | 0.04% | — | — | — | $930K |
Y95308105 WAVE LIFE SCIENCES LTD | 0.04% | $6.21 | $5.81 | -6.5% | $929.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AURA AURA BIOSCIENCES INC | 0.04% | $7.10 | $6.28 | -11.5% | $817.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AGLT AGILITY ROBOTICS INC | 0.04% | $17.45 | $11.62 | -33.4% | $581K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KZIA KAZIA THERAPEUTICS-SPON ADR | 0.04% | $14.08 | $9.59 | -31.9% | $590.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NUVL NUVALENT INC-A | 0.04% | $76.68 | $123.50 | +61.1% | $857.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LRMR LARIMAR THERAPEUTICS INC | 0.04% | $3.02 | $3.19 | +5.8% | $871.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VERA VERA THERAPEUTICS INC | 0.04% | $48.94 | $32.29 | -34.0% | $591.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADGM ADAGIO MEDICAL HOLDINGS INC | 0.04% | $1.04 | $0.15 | -85.3% | $184.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RNA ATRIUM THERAPEUTICS INC | 0.04% | $13.37 | $8.28 | -38.1% | $477.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TXMD THERAPEUTICSMD INC | 0.03% | $2.23* | $2.03 | -9.1% | $695.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IDYA IDEAYA BIOSCIENCES INC | 0.03% | $27.21 | $38.42 | +41.2% | $768.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SIBN SI-BONE INC | 0.03% | $15.29 | $18.80 | +23.0% | $846K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.03% | — | — | — | $720.2K | |
RPRX ROYALTY PHARMA PLC- CL A | 0.03% | $52.83 | $58.36 | +10.5% | $729.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EOLS EVOLUS INC | 0.03% | $6.27 | $8.00 | +27.6% | $800K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.03% | — | — | — | $667.8K | |
IBIO IBIO INC | 0.03% | $1.86 | $1.18 | -36.5% | $443.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
FWRD FORWARD AIR CORP | 0.03% | $19.53 | $13.51 | -30.8% | $651.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GERN GERON CORP | 0.03% | $2.04* | $1.23 | -39.7% | $622.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SYK STRYKER CORP | 0.03% | $314.84 | $275.39 | -12.5% | $550.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.03% | — | — | — | $623.2K | |
IOVA IOVANCE BIOTHERAPEUTICS INC | 0.03% | $4.16 | $14.82 | +256.3% | $2.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MGNX MACROGENICS INC | 0.03% | $4.09 | $3.86 | -5.6% | $501.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GILD GILEAD SCIENCES INC | 0.03% | $122.74 | $149.05 | +21.4% | $692.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NTRA NATERA INC | 0.03% | $229.09 | $413.31 | +80.4% | $887.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPTX SEAPORT THERAPEUTICS INC | 0.03% | $21.72 | $20.17 | -7.1% | $524.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.03% | — | — | — | $562.8K | |
ASMB ASSEMBLY BIOSCIENCES INC | 0.03% | $26.00 | $23.49 | -9.6% | $480.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
23256X407 CYBIN INC | 0.02% | $7.09 | $12.29 | +73.3% | $998.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BNTC BENITEC BIOPHARMA INC | 0.02% | $12.19 | $10.00 | -17.9% | $400K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PYPD POLYPID LTD | 0.02% | $4.34 | $5.27 | +21.4% | $547.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LUNG PULMONX CORP | 0.02% | $2.28 | $1.91 | -16.1% | $772.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MLTX MOONLAKE IMMUNOTHERAPEUTICS | 0.02% | $18.64 | $11.70 | -37.2% | $315.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GTERU GLOBA TERRA ACQUISITION CORP | 0.02% | $10.17 | $10.46 | +2.9% | $523K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TRAW TRAWS PHARMA INC | 0.02% | $0.92 | $0.59 | -35.3% | $354.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
USFR WISDOMTREE FLOATING RATE TRE | 0.02% | $50.24* | $50.39 | +0.3% | $503.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TECX TECTONIC THERAPEUTIC INC | 0.02% | $18.83 | $23.29 | +23.7% | $337.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MDGL MADRIGAL PHARMACEUTICALS INC | 0.02% | $431.22 | $503.96 | +16.9% | $451K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARVN ARVINAS INC | 0.02% | $7.02 | $7.74 | +10.2% | $445.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KIDS ORTHOPEDIATRICS CORP | 0.02% | $18.04 | $19.13 | +6.0% | $478.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
COGT COGENT BIOSCIENCES INC | 0.02% | $38.70 | $32.02 | -17.3% | $390.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PHAT PHATHOM PHARMACEUTICALS INC | 0.02% | $8.62 | $7.30 | -15.3% | $313.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MIRM MIRUM PHARMACEUTICALS INC | 0.02% | $92.38 | $85.48 | -7.5% | $333.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KPRX KIORA PHARMACEUTICALS INC | 0.02% | $4.11 | $2.56 | -37.7% | $429.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KURA KURA ONCOLOGY INC | 0.02% | $7.31 | $10.71 | +46.6% | $428.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTX CONTEXT THERAPEUTICS INC | 0.02% | $1.14 | $0.30 | -73.6% | $225.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STIP ISHARES 0-5 YEAR TIPS BOND E | 0.02% | $102.16 | $99.70 | -2.4% | $398.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KLRS KALARIS THERAPEUTICS INC | 0.02% | $8.44 | $2.89 | -65.8% | $289K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCAX BICARA THERAPEUTICS INC | 0.02% | $9.29 | $18.61 | +100.3% | $255.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MRK MERCK & CO. INC. | 0.02% | $82.12 | $145.31 | +77.0% | $456.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NMRA NEUMORA THERAPEUTICS INC | 0.02% | $1.71 | $0.60 | -65.2% | $125.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRTC IRHYTHM HOLDINGS INC | 0.02% | $118.95 | $113.66 | -4.4% | $341K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ACHV ACHIEVE LIFE SCIENCES INC | 0.02% | $3.35 | $8.09 | +141.4% | $435.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BABA ALIBABA GROUP HOLDING-SP ADR | 0.02% | $178.73 | $107.54 | -39.8% | $384.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
WW WW INTERNATIONAL INC-NEW | 0.02% | $27.37 | $15.46 | -43.5% | $329.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNSP CNS PHARMACEUTICALS INC | 0.02% | $4.78 | $5.30 | +10.9% | $371K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CBIO CRESCENT BIOPHARMA INC | 0.02% | $11.86 | $14.59 | +23.0% | $266.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BSX BOSTON SCIENTIFIC CORP | 0.01% | $79.05 | $43.65 | -44.8% | $327.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ALT ALTIMMUNE INC | 0.01% | $3.04 | $2.86 | -5.9% | $294.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VSTM VERASTEM INC | 0.01% | $5.21 | $8.05 | +54.6% | $610.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANTX AN2 THERAPEUTICS INC | 0.01% | $4.51 | $5.32 | +18.1% | $312.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DERM JOURNEY MEDICAL CORP | 0.01% | $7.08 | $6.84 | -3.4% | $270.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PCAPU PROCAP ACQUISITION CORP | 0.01% | $10.59 | $10.48 | -1.0% | $282.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PMVP PMV PHARMACEUTICALS INC | 0.01% | $1.38 | $1.67 | +20.9% | $335.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CMPX COMPASS THERAPEUTICS INC | 0.01% | $4.54 | $1.04 | -77.1% | $127K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JD JD.COM INC-ADR | 0.01% | $34.98 | $26.60 | -24.0% | $266K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RZLT REZOLUTE INC | 0.01% | $3.87 | $4.14 | +6.9% | $201.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANAB ANAPTYSBIO INC | 0.01% | $55.46 | $50.26 | -9.4% | $185.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NGNE NEUROGENE INC | 0.01% | $31.45 | $27.82 | -11.5% | $217K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IHI ISHARES U.S. MEDICAL DEVICES | 0.01% | $49.41 | $51.15 | +3.5% | $250.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RXST RXSIGHT INC | 0.01% | $5.16 | $4.90 | -5.0% | $245K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
COYA COYA THERAPEUTICS INC | 0.01% | $3.94 | $5.01 | +27.2% | $204.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCYC BICYCLE THERAPEUTICS PLC-ADR | 0.01% | $4.64 | $3.68 | -20.7% | $186.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CEPS CANTOR EQUITY PARTNERS VI -A | 0.01% | $10.10 | $10.20 | +1.0% | $204K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SCYX SCYNEXIS INC | 0.01% | $4.07 | $4.94 | +21.4% | $244K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PSNL PERSONALIS INC | 0.01% | $6.37 | $16.28 | +155.6% | $244.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QCLS Q/C TECHNOLOGIES INC | 0.01% | $3.45 | $3.90 | +13.0% | $195K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CABA CABALETTA BIO INC | 0.01% | $3.11 | $1.92 | -38.3% | $96K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RXRX RECURSION PHARMACEUTICALS-A | 0.01% | $5.42 | $4.13 | -23.7% | $169.3K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OGN ORGANON & CO | 0.01% | $9.47 | $13.70 | +44.6% | $137K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MIST MILESTONE PHARMACEUTICALS IN | 0.01% | $2.02 | $0.87 | -57.1% | $86.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NEUP NEUPHORIA THERAPEUTICS INC | 0.01% | $3.88 | $3.56 | -8.2% | $106.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STIM NEURONETICS INC | 0.01% | $1.45 | $2.34 | +61.4% | $234K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CMMB CHEMOMAB THERAPEUTICS LTD | 0.01% | $1.65 | $1.62 | -1.8% | $129.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STICall SOLIDION TECHNOLOGY INC | 0.01% | — | — | — | $125.4K |
VYGR VOYAGER THERAPEUTICS INC | 0.01% | $5.94* | $2.68 | -54.9% | $93.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TRDA ENTRADA THERAPEUTICS INC | 0.01% | $12.62 | $6.35 | -49.7% | $98.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VERU VERU INC | 0.01% | $2.14 | $2.66 | +24.3% | $93.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CAES CANTOR EQUITY PARTNERS VII-A | 0.00% | $10.09 | $10.10 | +0.1% | $101K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CLNN CLENE INC | 0.00% | $6.16 | $4.08 | -33.7% | $61.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VTGN VISTAGEN THERAPEUTICS INC | 0.00% | $0.95 | $0.23 | -76.1% | $79.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
54303L203 LONGEVERON INC | 0.00% | $1.04 | $0.70 | -32.4% | $76.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BMEA BIOMEA FUSION INC | 0.00% | $1.24 | $1.33 | +7.3% | $57.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LITS LITE STRATEGY INC | 0.00% | $2.42 | $1.32 | -45.5% | $88.8K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
471871202 JASPER THERAPEUTICS INC | 0.00% | $1.83 | $0.42 | -77.0% | $58.9K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ARDX ARDELYX INC | 0.00% | $5.99 | $3.42 | -42.9% | $37.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
38341P102 GOSSAMER BIO INC | 0.00% | $0.77* | $0.16 | -78.5% | $35K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
002120202 ATYR PHARMA INC | 0.00% | $0.72 | $0.60 | -17.3% | $30.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASPCR A SPAC III ACQUISITION CORP | 0.00% | $0.14 | $0.10 | -28.4% | $21.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PRQR PROQR THERAPEUTICS NV | 0.00% | $5.30 | $1.66 | -68.7% | $16.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BSAAR BEST SPAC I ACQUISITION - RT | 0.00% | $0.17 | $0.07 | -56.2% | $7.2K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CHRS COHERUS ONCOLOGY INC | 0.00% | $0.73 | $1.21 | +65.5% | $12.5K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price. * Held since before Dec 31, 2023, when our collected history starts, so the average starts from that quarter's price.
Changes in shares
Change in shares held vs Mar 31, 2026, for the 20 largest positions that changed. Bars are capped at ±100%; the label shows the actual change.
Sold out this quarter
Held on Mar 31, 2026 and not reported for Q2 2026.
| Stock | Prior weight | Prior shares | Prior value | Change |
|---|---|---|---|---|
| TERN TERNS PHARMACEUTICALS INC | 2.84% | 914,699 | $48.2M | EXIT |
| BEAM BEAM THERAPEUTICS INC | 2.03% | 1,446,375 | $34.5M | EXIT |
| SRRK SCHOLAR ROCK HOLDING CORP | 1.18% | 407,273 | $20M | EXIT |
| TERNCall TERNS PHARMACEUTICALS INC | 0.62% | 200,000 | $10.5M | EXIT |
| VRTX VERTEX PHARMACEUTICALS INC | 0.40% | 15,075 | $6.7M | EXIT |
| VRDN VIRIDIAN THERAPEUTICS INC | 0.35% | 304,422 | $6M | EXIT |
| 04351P101 ASCENDIS PHARMA A/S | 0.34% | 25,014 | $5.7M | EXIT |
| LLY ELI LILLY & CO | 0.27% | 5,060 | $4.7M | EXIT |
| DNTH DIANTHUS THERAPEUTICS INC | 0.27% | 55,000 | $4.6M | EXIT |
| BLTE BELITE BIO INC - ADR | 0.25% | 26,880 | $4.3M | EXIT |
| LQDAPut LIQUIDIA CORP | 0.22% | 100,000 | $3.8M | EXIT |
| ACLX ARCELLX INC | 0.22% | 32,084 | $3.7M | EXIT |
| AVBP ARRIVENT BIOPHARMA INC | 0.19% | 141,814 | $3.3M | EXIT |
| APLS APELLIS PHARMACEUTICALS INC | 0.17% | 72,500 | $2.9M | EXIT |
| MASI MASIMO CORP | 0.16% | 15,000 | $2.7M | EXIT |
| TFX TELEFLEX INC | 0.15% | 21,186 | $2.5M | EXIT |
| BIOA BIOAGE LABS INC | 0.14% | 135,560 | $2.4M | EXIT |
| ALKS ALKERMES PLC | 0.10% | 46,400 | $1.6M | EXIT |
| QURECall UNIQURE NV | 0.10% | 100,000 | $1.6M | EXIT |
| SLNO SOLENO THERAPEUTICS INC | 0.09% | 46,830 | $1.6M | EXIT |
| CNTA CENTESSA PHARMACEUTICALS LTD | 0.09% | 38,566 | $1.5M | EXIT |
| FOLD AMICUS THERAPEUTICS INC | 0.09% | 105,000 | $1.5M | EXIT |
| UNH UNITEDHEALTH GROUP INC | 0.09% | 5,501 | $1.5M | EXIT |
| SXT SENSIENT TECHNOLOGIES CORP | 0.08% | 15,000 | $1.3M | EXIT |
| SDGR SCHRODINGER INC | 0.07% | 101,500 | $1.2M | EXIT |
| KPTICall KARYOPHARM THERAPEUTICS INC | 0.07% | 205,200 | $1.1M | EXIT |
| FDMT 4D MOLECULAR THERAPEUTICS IN | 0.06% | 116,712 | $1.1M | EXIT |
| DAWN DAY ONE BIOPHARMACEUTICALS I | 0.06% | 49,923 | $1.1M | EXIT |
| BMY BRISTOL-MYERS SQUIBB CO | 0.06% | 17,500 | $1.1M | EXIT |
| BSAAU BEST SPAC I ACQUISITION CORP | 0.06% | 100,000 | $1M | EXIT |
| GH GUARDANT HEALTH INC | 0.05% | 10,000 | $923.7K | EXIT |
| 29286M105 ENGENE HOLDINGS INC | 0.05% | 133,686 | $910.4K | EXIT |
| ITGR INTEGER HOLDINGS CORP | 0.05% | 8,750 | $770K | EXIT |
| REPLCall REPLIMUNE GROUP INC | 0.05% | 100,000 | $765K | EXIT |
| KPTI KARYOPHARM THERAPEUTICS INC | 0.04% | 136,736 | $761.6K | EXIT |
| CGEM CULLINAN THERAPEUTICS INC | 0.04% | 50,000 | $710.5K | EXIT |
| 35168W103Call FRACTYL HEALTH INC | 0.04% | 1,428,571 | $654K | EXIT |
| KZR KEZAR LIFE SCIENCES INC | 0.04% | 81,933 | $607.9K | EXIT |
| JAZZ JAZZ PHARMACEUTICALS PLC | 0.03% | 3,000 | $567.2K | EXIT |
| ACRS ACLARIS THERAPEUTICS INC | 0.03% | 132,426 | $496.6K | EXIT |
| ELAN ELANCO ANIMAL HEALTH INC | 0.03% | 20,000 | $478.6K | EXIT |
| CORZ CORE SCIENTIFIC INC | 0.03% | 30,000 | $448.8K | EXIT |
| SNDX SYNDAX PHARMACEUTICALS INC | 0.02% | 17,500 | $408.8K | EXIT |
| MLTXCall MOONLAKE IMMUNOTHERAPEUTICS | 0.02% | 20,000 | $372.8K | EXIT |
| RGNX REGENXBIO INC | 0.02% | 44,416 | $372.2K | EXIT |
| ACET ADICET BIO INC | 0.02% | 53,827 | $366.6K | EXIT |
| LEGN LEGEND BIOTECH CORP-ADR | 0.02% | 20,000 | $361.8K | EXIT |
| SRZN SURROZEN INC | 0.02% | 12,000 | $349.6K | EXIT |
| NBIX NEUROCRINE BIOSCIENCES INC | 0.02% | 2,500 | $329.4K | EXIT |
| CORT CORCEPT THERAPEUTICS INC | 0.02% | 8,000 | $322.5K | EXIT |
| UPB UPSTREAM BIO INC | 0.02% | 35,000 | $315K | EXIT |
| ANNX ANNEXON INC | 0.02% | 55,000 | $304.7K | EXIT |
| JBIO JADE BIOSCIENCES INC | 0.02% | 20,000 | $281K | EXIT |
| RARE ULTRAGENYX PHARMACEUTICAL IN | 0.02% | 13,400 | $280.7K | EXIT |
| PANW PALO ALTO NETWORKS INC | 0.02% | 1,600 | $256.5K | EXIT |
| NTLA INTELLIA THERAPEUTICS INC | 0.01% | 19,517 | $250.2K | EXIT |
| CRWD CROWDSTRIKE HOLDINGS INC - A | 0.01% | 640 | $249.9K | EXIT |
| RBRK RUBRIK INC-A | 0.01% | 4,900 | $240K | EXIT |
| SGRY SURGERY PARTNERS INC | 0.01% | 20,000 | $238.4K | EXIT |
| QTTB Q32 BIO INC | 0.01% | 35,000 | $224.7K | EXIT |
| KALV KALVISTA PHARMACEUTICALS INC | 0.01% | 10,000 | $201.3K | EXIT |
| KYTX KYVERNA THERAPEUTICS INC | 0.01% | 22,428 | $193.6K | EXIT |
| NUVB NUVATION BIO INC | 0.01% | 43,500 | $186.6K | EXIT |
| LPCN LIPOCINE INC | 0.01% | 23,180 | $185.2K | EXIT |
| ERAS ERASCA INC | 0.01% | 10,000 | $161.8K | EXIT |
| STLN STARLING ONCOLOGY INC | 0.01% | 50,000 | $153.5K | EXIT |
| ARCT ARCTURUS THERAPEUTICS HOLDIN | 0.01% | 15,000 | $115.8K | EXIT |
| DSGN DESIGN THERAPEUTICS INC | 0.01% | 10,000 | $106.4K | EXIT |
| IMMX IMMIX BIOPHARMA INC | 0.01% | 10,000 | $91.1K | EXIT |
| KYNB KYNTRA BIO INC | 0.00% | 10,469 | $71K | EXIT |
| CLOV CLOVER HEALTH INVESTMENTS CO | 0.00% | 40,000 | $70.4K | EXIT |
| ESPR ESPERION THERAPEUTICS INC | 0.00% | 21,400 | $58.6K | EXIT |
| MREO MEREO BIOPHARMA GROUP PL-ADR | 0.00% | 150,000 | $49.5K | EXIT |
| AQST AQUESTIVE THERAPEUTICS INC | 0.00% | 10,000 | $41.5K | EXIT |
| 09077B104 BIOATLA INC | 0.00% | 228,107 | $36.7K | EXIT |
| 483119202 KALA BIO INC | 0.00% | 141,480 | $24.5K | EXIT |
| 22053A107 QUINCE THERAPEUTICS INC | 0.00% | 50,100 | $5.1K | EXIT |
| 22053A107Put QUINCE THERAPEUTICS INC | 0.00% | 50,000 | $5.1K | EXIT |
| 4525EP101 IMMUNIC INC | 0.00% | 30,000 | $0 | EXIT |
SEC filings for Q2 2026
- 13F-HR 0001940272-26-000015 · accepted Aug 14, 2026, 20:56 UTC